440 related articles for article (PubMed ID: 35104168)
21. Comparison of hydrophobicity scales for predicting biophysical properties of antibodies.
Waibl F; Fernández-Quintero ML; Wedl FS; Kettenberger H; Georges G; Liedl KR
Front Mol Biosci; 2022; 9():960194. PubMed ID: 36120542
[TBL] [Abstract][Full Text] [Related]
22. Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches.
Jain T; Boland T; Vásquez M
MAbs; 2023; 15(1):2200540. PubMed ID: 37072706
[TBL] [Abstract][Full Text] [Related]
23. Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling.
Raybould MIJ; Turnbull OM; Suter A; Guloglu B; Deane CM
Commun Biol; 2024 Jan; 7(1):62. PubMed ID: 38191620
[TBL] [Abstract][Full Text] [Related]
24. Developability assessment for monoclonal antibody drug candidates: a case study.
Garripelli VK; Wu Z; Gupta S
Pharm Dev Technol; 2021 Jan; 26(1):11-20. PubMed ID: 32986499
[TBL] [Abstract][Full Text] [Related]
25. A machine learning strategy for the identification of key
Waight AB; Prihoda D; Shrestha R; Metcalf K; Bailly M; Ancona M; Widatalla T; Rollins Z; Cheng AC; Bitton DA; Fayadat-Dilman L
MAbs; 2023; 15(1):2248671. PubMed ID: 37610144
[TBL] [Abstract][Full Text] [Related]
26. Development of in silico models to predict viscosity and mouse clearance using a comprehensive analytical data set collected on 83 scaffold-consistent monoclonal antibodies.
Mock M; Jacobitz AW; Langmead CJ; Sudom A; Yoo D; Humphreys SC; Alday M; Alekseychyk L; Angell N; Bi V; Catterall H; Chen CC; Chou HT; Conner KP; Cook KD; Correia AR; Dykstra A; Ghimire-Rijal S; Graham K; Grandsard P; Huh J; Hui JO; Jain M; Jann V; Jia L; Johnstone S; Khanal N; Kolvenbach C; Narhi L; Padaki R; Pelegri-O'Day EM; Qi W; Razinkov V; Rice AJ; Smith R; Spahr C; Stevens J; Sun Y; Thomas VA; van Driesche S; Vernon R; Wagner V; Walker KW; Wei Y; Winters D; Yang M; Campuzano IDG
MAbs; 2023; 15(1):2256745. PubMed ID: 37698932
[TBL] [Abstract][Full Text] [Related]
27. Modeling the impact of amino acid substitution in a monoclonal antibody on cation exchange chromatography.
Saleh D; Hess R; Ahlers-Hesse M; Beckert N; Schönberger M; Rischawy F; Wang G; Bauer J; Blech M; Kluters S; Studts J; Hubbuch J
Biotechnol Bioeng; 2021 Aug; 118(8):2923-2933. PubMed ID: 33871060
[TBL] [Abstract][Full Text] [Related]
28. In Silico Prediction of Diffusion Interaction Parameter (k
Tomar DS; Singh SK; Li L; Broulidakis MP; Kumar S
Pharm Res; 2018 Aug; 35(10):193. PubMed ID: 30128780
[TBL] [Abstract][Full Text] [Related]
29. Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties.
Svilenov HL; Arosio P; Menzen T; Tessier P; Sormanni P
MAbs; 2023; 15(1):2164459. PubMed ID: 36629855
[TBL] [Abstract][Full Text] [Related]
30. In silico prediction of post-translational modifications in therapeutic antibodies.
Vatsa S
MAbs; 2022; 14(1):2023938. PubMed ID: 35040751
[TBL] [Abstract][Full Text] [Related]
31. Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling.
Park E; Izadi S
MAbs; 2024; 16(1):2362788. PubMed ID: 38853585
[No Abstract] [Full Text] [Related]
32. An accelerated surface-mediated stress assay of antibody instability for developability studies.
Kopp MRG; Wolf Pérez AM; Zucca MV; Capasso Palmiero U; Friedrichsen B; Lorenzen N; Arosio P
MAbs; 2020; 12(1):1815995. PubMed ID: 32954930
[TBL] [Abstract][Full Text] [Related]
33. Boosting antibody developability through rational sequence optimization.
Seeliger D; Schulz P; Litzenburger T; Spitz J; Hoerer S; Blech M; Enenkel B; Studts JM; Garidel P; Karow AR
MAbs; 2015; 7(3):505-15. PubMed ID: 25759214
[TBL] [Abstract][Full Text] [Related]
34. Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection.
Lavoisier A; Schlaeppi JM
MAbs; 2015; 7(1):77-83. PubMed ID: 25514497
[TBL] [Abstract][Full Text] [Related]
35. Intrinsic physicochemical profile of marketed antibody-based biotherapeutics.
Ahmed L; Gupta P; Martin KP; Scheer JM; Nixon AE; Kumar S
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34504010
[TBL] [Abstract][Full Text] [Related]
36. Cross-Interaction Chromatography-Based QSAR Model for Early-Stage Screening to Facilitate Enhanced Developability of Monoclonal Antibody Therapeutics.
Kizhedath A; Karlberg M; Glassey J
Biotechnol J; 2019 Aug; 14(8):e1800696. PubMed ID: 30810283
[TBL] [Abstract][Full Text] [Related]
37. Pragmatic mAb lead molecule engineering from a developability perspective.
Chi B; De Oliveira G; Gallagher T; Mitchell L; Knightley L; Gonzalez CC; Russell S; Germaschewski V; Pearce C; Sellick CA
Biotechnol Bioeng; 2021 Oct; 118(10):3733-3743. PubMed ID: 33913507
[TBL] [Abstract][Full Text] [Related]
38. Improving the Developability of an Antigen Binding Fragment by Aspartate Substitutions.
Sakhnini LI; Greisen PJ; Wiberg C; Bozoky Z; Lund S; Wolf Perez AM; Karkov HS; Huus K; Hansen JJ; Bülow L; Lorenzen N; Dainiak MB; Pedersen AK
Biochemistry; 2019 Jun; 58(24):2750-2759. PubMed ID: 31117388
[TBL] [Abstract][Full Text] [Related]
39. Advancing Therapeutic Protein Discovery and Development through Comprehensive Computational and Biophysical Characterization.
Gentiluomo L; Svilenov HL; Augustijn D; El Bialy I; Greco ML; Kulakova A; Indrakumar S; Mahapatra S; Morales MM; Pohl C; Roche A; Tosstorff A; Curtis R; Derrick JP; Nørgaard A; Khan TA; Peters GHJ; Pluen A; Rinnan Å; Streicher WW; van der Walle CF; Uddin S; Winter G; Roessner D; Harris P; Frieß W
Mol Pharm; 2020 Feb; 17(2):426-440. PubMed ID: 31790599
[TBL] [Abstract][Full Text] [Related]
40. Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope.
Kizhedath A; Wilkinson S; Glassey J
Arch Toxicol; 2017 Apr; 91(4):1595-1612. PubMed ID: 27766364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
